[144] Aquestive Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Aquestive Therapeutics (AQST) filing a Form 144 notifies a proposed sale of 15,000 common shares through Merrill Lynch on Nasdaq, with an aggregate market value of $79,500. The shares were originally acquired under a stock option granted by the issuer and vested on 05/11/2018; the filer reports acquiring 49,439 shares on that date. The filing lists approximately 99,723,635 shares outstanding, making the proposed sale a very small fraction of total shares. The filer certifies they are not aware of undisclosed material adverse information and provides the standard Rule 144 representations required for such sales.

Positive

• Regulatory compliance: The filer submitted a Form 144 disclosing the proposed sale consistent with Rule 144 requirements
• Transparent transaction details: Broker, acquisition date, nature of acquisition (stock option), and shares outstanding are provided

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider sale notice; size is immaterial to company capitalization and appears compliant with Rule 144.

The Form 144 reports a proposed sale of 15,000 common shares via Merrill Lynch with an aggregate market value of $79,500, scheduled approximately 09/05/2025. The shares were acquired under a stock option that vested on 05/11/2018 and the filer indicates total outstanding shares of 99,723,635. Based on these figures the proposed sale represents roughly 0.015% of outstanding shares, implying negligible market impact. The filing includes the standard certification that no undisclosed material adverse information is known to the seller, and no prior sales in the past three months are reported.

Corporate Governance Expert

TL;DR: Disclosure aligns with insider reporting duties; supports transparency though provides limited strategic insight.

The notice fulfills the procedural requirement to disclose a proposed sale under Rule 144 and identifies the broker, acquisition method (stock option), vesting/payment date, and the amount acquired. This supports market transparency regarding insider liquidity. The filing does not provide additional context such as plan adoption dates under Rule 10b5-1, and it contains no information suggesting governance changes or material events affecting the issuer.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 100 Campus Drive Florham Park NJ 07932	15000	79500.00	99723635	09/05/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/11/2018	Stock Option	Issuer			49439	05/11/2018	Vesting

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the AQST Form 144 report?

The Form 144 reports a proposed sale of 15,000 common shares via Merrill Lynch with an aggregate market value of $79,500 on Nasdaq.

When were the shares being sold originally acquired?

The shares were acquired on 05/11/2018 through a stock option that vested on that date; the filer reports acquiring 49,439 shares then.

How large is the proposed sale relative to AQST's outstanding shares?

The filing lists 99,723,635 shares outstanding; 15,000 shares represent approximately 0.015% of outstanding shares, indicating minimal size.

Does the filing report any securities sold by the filer in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

Does the filer claim any undisclosed material information about AQST?

The filer represents they do not know any material adverse information regarding the issuer that has not been publicly disclosed.